SEAL

Trial description
A Phase 2-3, multicenter, randomized, doubleblind study of selinexor (KPT-330) versus placebo in patients with advanced unresectable dedifferentiated liposarcoma (DDLS)
Contact name
Dr Helen Hatcher
Trial start date
Wednesday, November 7, 2018
Trial end date
Monday, August 31, 2020
Trial tumour type
Sarcoma
Show on Radiotherapy
No